CJC-1295 DAC: Complete Research Guide

What is CJC-1295 DAC?

CJC-1295 DAC (Drug Affinity Complex) is a synthetic growth hormone-releasing hormone (GHRH) analog that has become increasingly popular in research and athletic communities. The “DAC” modification—a drug affinity complex using lysine—extends the peptide’s half-life from minutes to days, making it significantly more practical for research applications than earlier GH-releasing peptides. This article covers the mechanism of action, research findings, reconstitution protocols, storage requirements, and practical considerations for researchers working with CJC-1295 DAC.

Mechanism of action: how CJC-1295 DAC works

GHRH receptor signaling

CJC-1295 DAC functions by binding to GHRH receptors in the anterior pituitary gland. GHRH (growth hormone-releasing hormone) is a natural peptide hormone that stimulates the synthesis and secretion of growth hormone (GH). CJC-1295 DAC acts as a synthetic GHRH analog, mimicking this signaling cascade.

When CJC-1295 DAC binds to pituitary GHRH receptors, it initiates a cascade of intracellular signaling through G-protein coupled receptor (GPCR) pathways. This leads to increased cAMP levels, activation of protein kinase A (PKA), and ultimately increased gene transcription for growth hormone production and release.

The DAC modification: extended half-life

The critical innovation of CJC-1295 DAC is the Drug Affinity Complex modification. Native GHRH peptides are rapidly degraded by dipeptidyl peptidase-4 (DPP-4) enzymes in circulation, resulting in a half-life of just 7-15 minutes. The DAC modification involves conjugation with a lysine-based complex that creates an affinity binding to serum albumin.

This albumin-binding characteristic dramatically extends the peptide’s circulating half-life to approximately 6-8 days. The extended half-life means:

• Less frequent dosing required (typically once per week vs. multiple times daily)
• More stable and predictable GH secretion patterns
• Improved convenience for long-term research protocols
• Reduced handling and reconstitution frequency

Pulsatile vs. continuous GH release

CJC-1295 DAC stimulates GH release in a more physiologically relevant pulsatile pattern compared to continuous infusion methods. Natural GH secretion occurs in distinct pulses, typically 5-7 times daily, with the largest pulse occurring during sleep. CJC-1295 DAC helps preserve this pulsatile pattern, which is thought to be important for optimal metabolic effects.

Research studies: what the literature shows

Pre-clinical and animal research

Animal models have shown CJC-1295 DAC to effectively stimulate GH release and support anabolic tissue development. Effects studied include bone mineral density improvements, lean tissue accretion, and metabolic parameter changes. Direct translation from animal to human research remains an active area of investigation.

Storage and stability: maximizing peptide longevity

Lyophilized (unreconstituted) storage

Lyophilized CJC-1295 DAC is extremely stable when properly stored:

• Temperature: 2-8°C (refrigerator) is ideal. Room temperature storage (20-25°C) is acceptable short-term but will reduce shelf life.
• Light protection: Store in the original amber/brown glass vial. Protect from direct sunlight and UV exposure.
• Humidity: Keep in a dry environment. Vacuum-sealed vials provide additional protection; silica desiccant packets help absorb moisture.
• Expected shelf life: 2-3 years when stored at 2-8°C; potentially 1-2 years at room temperature (though refrigeration is strongly preferred).

Reconstituted solution storage

Once dissolved in bacteriostatic water, CJC-1295 DAC stability decreases:

• Temperature: Must be stored at 2-8°C (refrigerator). Do not allow to freeze or exceed 25°C.
• Duration: Typically stable for 2-4 weeks in solution at 2-8°C, though some researchers report stability up to 8 weeks. Bacteriostatic water’s antimicrobial properties help extend this window.
• Container: Use sterile glass vials with rubber septa. Avoid plastic syringes for long-term storage as some plastics may interact with the peptide.
• Sterility: Always use sterile technique when reconstituting and withdrawing doses. Any contamination will significantly reduce shelf life.

Freeze-thaw considerations

Freezing reconstituted CJC-1295 DAC is not recommended. Ice crystal formation can damage the peptide structure. If frozen reconstituted solution must be used, allow it to thaw slowly at 2-8°C before use, and discard any solution that shows visible particulates or discoloration.

Frequently asked questions

How long does CJC-1295 DAC take to work?

Peak GH levels are typically observed 30-60 minutes after injection. The extended half-life means GH elevation persists for days. Some research suggests steady-state GH elevation builds over several weeks of repeated dosing.

Can CJC-1295 DAC be combined with other peptides?

Yes. CJC-1295 DAC is commonly stacked with Ipamorelin or other GHRP peptides to potentiate GH release. See our Research Peptide Stacks guide for more details.

What is a certificate of analysis (COA)?

A COA is a quality assurance document detailing purity, potency, and microbial testing. All CertaPeptides products include a COA. Learn how to read one in our How to Read a COA guide.

Is CJC-1295 DAC legal?

CJC-1295 DAC is sold for research purposes only. Researchers are responsible for understanding local regulations governing peptide research in their jurisdiction. See our Research Peptide Regulations in Europe 2026 guide.

Conclusion

CJC-1295 DAC’s extended half-life and sustained GH stimulation make it a practical choice for growth hormone research protocols that require infrequent dosing. Proper reconstitution, storage, and handling are critical to maintaining peptide integrity. Whether used as a standalone research tool or combined with a GHRP peptide like Ipamorelin, CJC-1295 DAC is a well-characterized option backed by published human and animal data.

For questions about product selection or reconstitution protocols, visit our FAQ or contact our research support team.

References

1. Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805. PMID: 16352683.
2. Alba M, et al. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology–Endocrinology and Metabolism, 291(6), E1290-E1294. PMID: 16339414.
3. Ionescu M, Bhatt DL, et al. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797. PMID: 17018654.
4. Nass R, et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Annals of Internal Medicine, 149(9), 601-611. PMID: 18981485.